Takeda grows in gene therapies again with $2bn Code Bio deal
pharmaphorum
FEBRUARY 23, 2022
Code Bio’s 3DNA vectors are based on pieces of synthetic DNA linked together to form a scaffold that can carry a larger gene sequence than viral vectors, and according to the biotech don’t trigger an immune response which might cause side effects or limit the potential for re-dosing.
105 
Let's personalize your content